THRD(Delisted)
Third Harmonic Bio (THRD) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Third Harmonic Bio market cap is -- and enterprise value is --.
Share Statistics
Third Harmonic Bio has 45.13M shares outstanding, with a free float of 22.29M.
Valuation Ratios
Third Harmonic Bio's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Solvency
Third Harmonic Bio debt-to-equity ratio is 0 and debt-to-assets ratio is 0.03.
Liquidity
Third Harmonic Bio's current ratio is 54.1, quick ratio is 54.1, and cash ratio is 53.24, showing its short-term liquidity position.
Return on Capital
Third Harmonic Bio's ROE is -19.94%, ROA is -19.42%, and ROIC is -24.73%, showing its return on capital profile.
Profitability
Third Harmonic Bio gross margin is --, operating margin is --, and net margin is --.
Operating Efficiency
Third Harmonic Bio's asset turnover is --, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
Third Harmonic Bio's revenue is --, gross profit is --, net income is -53.45M, and EBITDA is -66.25M.
Balance Sheet
Third Harmonic Bio's total debt is 0, net debt is 0, total equity is 272.62M, and cash is 271.61M.
Cash Flow Statement
Third Harmonic Bio's operating cash flow is -41.69M, free cash flow is -41.70M, and CapEx is --.
Dividends & Yields
Third Harmonic Bio dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Third Harmonic Bio's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A clinical-stage biopharmaceutical company that develops medicine for allergy and inflammation
Per Share Metrics
Third Harmonic Bio's EPS is -1.24, book value per share is 6.06, and free cash flow per share is --.
